Format
Items per page
Sort by

Send to:

Choose Destination

Results: 10

Cited In for PubMed (Select 20645430)

1.

Repurposing Drugs in Oncology (ReDO)-clarithromycin as an anti-cancer agent.

Van Nuffel AM, Sukhatme V, Pantziarka P, Meheus L, Sukhatme VP, Bouche G.

Ecancermedicalscience. 2015 Feb 24;9:513. doi: 10.3332/ecancer.2015.513. eCollection 2015.

2.

Ectopic microRNA-150-5p transcription sensitizes glucocorticoid therapy response in MM1S multiple myeloma cells but fails to overcome hormone therapy resistance in MM1R cells.

Palagani A, Op de Beeck K, Naulaerts S, Diddens J, Sekhar Chirumamilla C, Van Camp G, Laukens K, Heyninck K, Gerlo S, Mestdagh P, Vandesompele J, Berghe WV.

PLoS One. 2014 Dec 4;9(12):e113842. doi: 10.1371/journal.pone.0113842. eCollection 2014.

3.

Salvage therapy of multiple myeloma: the new generation drugs.

Romano A, Conticello C, Cavalli M, Vetro C, Di Raimondo C, Di Martina V, Schinocca E, La Fauci A, Parrinello NL, Chiarenza A, Di Raimondo F.

Biomed Res Int. 2014;2014:456037. doi: 10.1155/2014/456037. Epub 2014 May 19. Review.

4.

Clarithromycin overcomes resistance to lenalidomide and dexamethasone in multiple myeloma.

Ghosh N, Tucker N, Zahurak M, Wozney J, Borrello I, Huff CA.

Am J Hematol. 2014 Aug;89(8):E116-20. doi: 10.1002/ajh.23733. Epub 2014 Apr 26.

5.

Macrolide antibiotics block autophagy flux and sensitize to bortezomib via endoplasmic reticulum stress-mediated CHOP induction in myeloma cells.

Moriya S, Che XF, Komatsu S, Abe A, Kawaguchi T, Gotoh A, Inazu M, Tomoda A, Miyazawa K.

Int J Oncol. 2013 May;42(5):1541-50. doi: 10.3892/ijo.2013.1870. Epub 2013 Mar 28.

6.

BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma.

Rossi A, Mark T, Jayabalan D, Christos P, Zafar F, Pekle K, Pearse R, Chen-Kiang S, Coleman M, Niesvizky R.

Blood. 2013 Mar 14;121(11):1982-5. doi: 10.1182/blood-2012-08-448563. Epub 2013 Jan 8.

7.

Biological activity of lenalidomide and its underlying therapeutic effects in multiple myeloma.

Martiniani R, Di Loreto V, Di Sano C, Lombardo A, Liberati AM.

Adv Hematol. 2012;2012:842945. doi: 10.1155/2012/842945. Epub 2012 Aug 2.

8.

Lenalidomide in the treatment of young patients with multiple myeloma: from induction to consolidation/maintenance therapy.

Lupo B, Palumbo A.

Adv Hematol. 2012;2012:906247. doi: 10.1155/2012/906247. Epub 2012 Jul 11.

9.

Lenalidomide before and after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.

Tuchman SA, Chao NJ, Gasparetto CG.

Adv Hematol. 2012;2012:712613. doi: 10.1155/2012/712613. Epub 2012 May 30.

10.

Clarithromycin enhances bortezomib-induced cytotoxicity via endoplasmic reticulum stress-mediated CHOP (GADD153) induction and autophagy in breast cancer cells.

Komatsu S, Miyazawa K, Moriya S, Takase A, Naito M, Inazu M, Kohno N, Itoh M, Tomoda A.

Int J Oncol. 2012 Apr;40(4):1029-39. doi: 10.3892/ijo.2011.1317. Epub 2011 Dec 23.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk